scholarly journals A comparative assessment of adipose-derived stem cells from subcutaneous and visceral fat as a potential cell source for knee osteoarthritis treatment

2017 ◽  
Vol 21 (9) ◽  
pp. 2153-2162 ◽  
Author(s):  
Yan Tang ◽  
Zhang-yi Pan ◽  
Ying Zou ◽  
Yi He ◽  
Peng-yuan Yang ◽  
...  
Keyword(s):  
Stem Cells ◽  
Knee Osteoarthritis ◽  
Visceral Fat ◽  
Comparative Assessment ◽  
Adipose Derived Stem Cells ◽  
Osteoarthritis Treatment ◽  
Cell Source

Preliminary results of autologous adipose-derived stem cells in early knee osteoarthritis: identification of a subpopulation with greater response

2018 ◽  
Vol 43 (1) ◽  
pp. 7-13 ◽  
Author(s):  
Alfredo Schiavone Panni ◽  
Michele Vasso ◽  
Adriano Braile ◽  
Giuseppe Toro ◽  
Annalisa De Cicco ◽  
...  
Keyword(s):  
Stem Cells ◽  
Knee Osteoarthritis ◽  
Adipose Derived Stem Cells ◽  
Preliminary Results

Injectable Hydrogel Mediated Delivery of Gene-Engineered Adipose-Derived Stem Cells for Enhanced Osteoarthritis Treatment

2021 ◽  
Author(s):  
Wei Yu ◽  
Bin Hu ◽  
Kofi Oti Boakye-Yiadom ◽  
William Ho ◽  
Qijing Chen ◽  
...  
Keyword(s):  
Stem Cells ◽  
Therapeutic Agent ◽  
Degenerative Joint Disease ◽  
Joint Disease ◽  
Adipose Derived Stem Cells ◽  
Injectable Hydrogel ◽  
Disease Modifying Therapies ◽  
Osteoarthritis Treatment ◽  
Disease Modifying ◽  
Promising Therapeutic Agent

Osteoarthritis (OA), a chronic and degenerative joint disease, remains a challenge in treatment due to the lack of disease-modifying therapies. As a promising therapeutic agent, adipose-derived stem cells (ADSCs) perform...

Sirtuins 1–7 expression in human adipose-derived stem cells from subcutaneous and visceral fat depots: influence of obesity and hypoxia

Endocrine ◽  
2016 ◽  
Vol 57 (3) ◽  
pp. 455-463 ◽  
Author(s):  
Stefania Mariani ◽  
Giuliana Di Rocco ◽  
Gabriele Toietta ◽  
Matteo A. Russo ◽  
Elisa Petrangeli ◽  
...  
Keyword(s):  
Stem Cells ◽  
Visceral Fat ◽  
Adipose Derived Stem Cells ◽  
Fat Depots

scholarly journals Treatment of knee osteoarthritis with intra-articular injection of allogeneic adipose-derived stem cells (ADSCs) ELIXCYTE®: a phase I/II, randomized, active-control, single-blind, multiple-center clinical trial

2021 ◽  
Vol 12 (1) ◽  
Author(s):  
Cheng-Fong Chen ◽  
Chih-Chien Hu ◽  
Chen-Te Wu ◽  
Hung-Ta H. Wu ◽  
Chun-Shin Chang ◽  
...  
Keyword(s):  
Stem Cells ◽  
Adverse Events ◽  
Knee Osteoarthritis ◽  
Pain Score ◽  
Active Control ◽  
Womac Pain ◽  
Adipose Derived Stem Cells ◽  
Serious Adverse Events ◽  
Treatment Visit ◽  
Womac Pain Score

Abstract Objective To evaluate the safety and efficacy of intra-articular (IA) injection of allogeneic adipose-derived stem cells (ADSCs) ELIXCYTE® for knee osteoarthritis. Methods This was a patient-blind, randomized, active-control trial consisted of 4 arms including hyaluronic acid (HA) control and 3 ELIXCYTE® doses. A total of 64 subjects were screened, and 57 subjects were randomized. The primary endpoints included the changes from baseline to post-treatment visit of Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) pain score at Week 24 and the incidence of adverse events (AEs) and serious adverse events (SAEs). Results No ELIXCYTE®-related serious adverse events were reported during 96 weeks of follow-up and no suspected unexpected serious adverse reaction (SUSAR) or death was reported. The changes of the primary endpoint, WOMAC pain score at Week 24, showed significant differences in all ELIXCYTE® groups, as well as in HA groups between post-treatment visit and baseline. The ELIXCYTE® groups revealed significant decreases at Week 4 compared to HA group in WOMAC total scores, stiffness scores, functional limitation scores suggested the potential of ELIXCYTE® in earlier onset compared to those from HA. The significant differences of visual analog scale (VAS) pain score and Knee Society Clinical Rating System (KSCRS) functional activities score at Week 48 after ELIXCYTE® administration suggested the potential of ELIXCYTE® in the longer duration of the effectiveness compared to HA group. Conclusions ELIXCYTE® for knee osteoarthritis treatment was effective, safe, and well-tolerated. The efficacy results were showed that ELIXCYTE® conferred the earlier onset of reductions in pain scores and improvements in functional scores than HA group. Trial registration: ClinicalTrials.gov Identifier: NCT02784964. Registered 16 May, 2016—Retrospectively registered, https://clinicaltrials.gov/ct2/show/NCT02784964

Sign in / Sign up

Export Citation Format

Share Document